Evan Lippman

EVP, Business Development, Teva Pharmaceuticals

Bought, 12 months

$0.0M

Sold, 12 months

$2.2M

Companies

Latest trade

Aug 17, 2026

Companies

Teva PharmaceuticalsEVP, Business Development −$2.2M

Trades

TEVA Sold 18,600 shares at $36.57 · planned $0.7M Aug 17

TEVA Sold 41,658 shares at $35.58 · planned $1.5M May 14

Open-market trades from SEC Form 4 only: no grants, option exercises or gifts. People are matched by the name on their filings, so two people with the same name share this page. For information only — not investment advice.